User login
Key clinical point: Fecal microbiota transplantation (FMT) reduced disease severity, improved microbiome α-diversity, and demonstrated a favorable safety profile in patients with refractory irritable bowel syndrome (IBS).
Major finding: The IBS severity index improved significantly at 12 weeks after FMT (P = .001), with 58.8% of patients being responders (≥50-point decrease in IBS severity index). Responders showed a significant increase in the median α-diversity index (P = .017), increased abundance of Neisseria and Akkermansia bacteria, and decreased abundance of Desulfovibrio and Delftia bacteria. No severe adverse events were reported.
Study details Findings are from a prospective study including 17 patients with refractory IBS who received FMT under colonoscopy.
Disclosures: This study was partly supported by the Japan Society for the Promotion of Science. The authors declared no conflicts of interest.
Source: Hamazaki M et al. Fecal microbiota transplantation in the treatment of irritable bowel syndrome: A single-center prospective study in Japan. BMC Gastroenterol. 2022;22:342 (Jul 14). Doi: 10.1186/s12876-022-02408-5
Key clinical point: Fecal microbiota transplantation (FMT) reduced disease severity, improved microbiome α-diversity, and demonstrated a favorable safety profile in patients with refractory irritable bowel syndrome (IBS).
Major finding: The IBS severity index improved significantly at 12 weeks after FMT (P = .001), with 58.8% of patients being responders (≥50-point decrease in IBS severity index). Responders showed a significant increase in the median α-diversity index (P = .017), increased abundance of Neisseria and Akkermansia bacteria, and decreased abundance of Desulfovibrio and Delftia bacteria. No severe adverse events were reported.
Study details Findings are from a prospective study including 17 patients with refractory IBS who received FMT under colonoscopy.
Disclosures: This study was partly supported by the Japan Society for the Promotion of Science. The authors declared no conflicts of interest.
Source: Hamazaki M et al. Fecal microbiota transplantation in the treatment of irritable bowel syndrome: A single-center prospective study in Japan. BMC Gastroenterol. 2022;22:342 (Jul 14). Doi: 10.1186/s12876-022-02408-5
Key clinical point: Fecal microbiota transplantation (FMT) reduced disease severity, improved microbiome α-diversity, and demonstrated a favorable safety profile in patients with refractory irritable bowel syndrome (IBS).
Major finding: The IBS severity index improved significantly at 12 weeks after FMT (P = .001), with 58.8% of patients being responders (≥50-point decrease in IBS severity index). Responders showed a significant increase in the median α-diversity index (P = .017), increased abundance of Neisseria and Akkermansia bacteria, and decreased abundance of Desulfovibrio and Delftia bacteria. No severe adverse events were reported.
Study details Findings are from a prospective study including 17 patients with refractory IBS who received FMT under colonoscopy.
Disclosures: This study was partly supported by the Japan Society for the Promotion of Science. The authors declared no conflicts of interest.
Source: Hamazaki M et al. Fecal microbiota transplantation in the treatment of irritable bowel syndrome: A single-center prospective study in Japan. BMC Gastroenterol. 2022;22:342 (Jul 14). Doi: 10.1186/s12876-022-02408-5